Literature DB >> 24510244

Copy number variation in CCND1 gene is implicated in the pathogenesis of sporadic parathyroid carcinoma.

Lin Zhao1, Li-hao Sun, Dong-mei Liu, Xiao-yan He, Bei Tao, Guang Ning, Jian-min Liu, Hong-yan Zhao.   

Abstract

BACKGROUND: The molecular bases for parathyroid carcinomas present in conjunction with sporadic primary hyperparathyroidism are not fully elucidated. Gene copy number variations (CNVs) play an important role in tumorigenesis. The aim of the current study was to explore whether the CNVs of specific tumor-associated genes are involved in parathyroid carcinogenesis.
METHODS: A multiplex ligation-dependent probe amplification method was used to compare differences in copy number in 39 common tumor-associated genes among 7 patients with parathyroid carcinoma and 14 age- and sex-matched subjects with parathyroid adenoma.
RESULTS: It was shown that amplification of CCND1, a gene encoding cyclin D1, was more prevalent in parathyroid carcinomas than in adenomas (71 vs. 21 %, p = 0.056). This result was confirmed quantitatively by real-time polymerase chain reaction. Expression of CCND1 mRNA level was significantly higher in carcinomas than in adenomas (p = 0.003). Western blot and immunohistochemical analysis also demonstrated higher expression of CCND1 in carcinoma specimens than in adenoma samples.
CONCLUSIONS: It is thus inferred that gain in copy number of CCND1 is implicated in the molecular pathogenesis of parathyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24510244     DOI: 10.1007/s00268-014-2455-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  37 in total

Review 1.  Clinical review 122: Parathyroid carcinoma.

Authors:  E Shane
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

2.  Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study.

Authors:  E D Hsi; L R Zukerberg; W I Yang; A Arnold
Journal:  J Clin Endocrinol Metab       Date:  1996-05       Impact factor: 5.958

3.  Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism.

Authors:  Léopoldine Bricaire; Marie-Françoise Odou; Catherine Cardot-Bauters; Brigitte Delemer; Marie-Odile North; Sylvie Salenave; Delphine Vezzosi; Jean-Marc Kuhn; Arnaud Murat; Philippe Caron; Jean-Louis Sadoul; Caroline Silve; Philippe Chanson; Anne Barlier; Eric Clauser; Nicole Porchet; Lionel Groussin
Journal:  J Clin Endocrinol Metab       Date:  2013-01-04       Impact factor: 5.958

4.  Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.

Authors:  Geoffrey E Woodard; Ling Lin; Jian-Hua Zhang; Sunita K Agarwal; Stephen J Marx; William F Simonds
Journal:  Oncogene       Date:  2005-02-10       Impact factor: 9.867

5.  Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype.

Authors:  Carola J Haven; Viive M Howell; Paul H C Eilers; Robert Dunne; Masayuki Takahashi; Marjo van Puijenbroek; Kyle Furge; Job Kievit; Min-Han Tan; Gert Jan Fleuren; Bruce G Robinson; Leigh W Delbridge; Jeanette Philips; Anne E Nelson; Ulf Krause; Henning Dralle; Cuong Hoang-Vu; Oliver Gimm; Hans Morreau; Deborah J Marsh; Bin T Teh
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

6.  Distinction in gene expression profiles demonstrated in parathyroid adenomas by high-density oligoarray technology.

Authors:  Lars Forsberg; Erik Björck; Jamileh Hashemi; Jan Zedenius; Anders Höög; Lars-Ove Farnebo; Mark Reimers; Catharina Larsson
Journal:  Eur J Endocrinol       Date:  2005-03       Impact factor: 6.664

7.  Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.

Authors:  Elisabet Ognedal Berge; Stian Knappskog; Stephanie Geisler; Vidar Staalesen; Marec Pacal; Anne-Lise Børresen-Dale; Pål Puntervoll; Johan Richard Lillehaug; Per Eystein Lønning
Journal:  Mol Cancer       Date:  2010-07-01       Impact factor: 27.401

8.  The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center.

Authors:  Lin Zhao; Jian-Min Liu; Xiao-Yan He; Hong-Yan Zhao; Li-Hao Sun; Bei Tao; Min-Jia Zhang; Xi Chen; Wei-Qing Wang; Guang Ning
Journal:  J Clin Endocrinol Metab       Date:  2013-01-30       Impact factor: 5.958

Review 9.  Parathyroid carcinoma: challenges in diagnosis and treatment.

Authors:  Arash Mohebati; Ashok Shaha; Jatin Shah
Journal:  Hematol Oncol Clin North Am       Date:  2012-10-05       Impact factor: 3.722

10.  Systematic review of primary hyperparathyroidism in India: the past, present, and the future trends.

Authors:  P V Pradeep; B Jayashree; Anjali Mishra; S K Mishra
Journal:  Int J Endocrinol       Date:  2011-05-26       Impact factor: 3.257

View more
  10 in total

1.  CDK4/6 Dependence of Cyclin D1-Driven Parathyroid Neoplasia in Transgenic Mice.

Authors:  Jessica Costa-Guda; Kristin Corrado; Justin Bellizzi; Robert Romano; Elizabeth Saria; Kirsten Saucier; Madison Rose; Samip Shah; Cynthia Alander; Sanjay Mallya; Andrew Arnold
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736

Review 2.  Molecular genetics in primary hyperparathyroidism: the role of genetic tests in differential diagnosis, disease prevention strategy, and therapeutic planning. A 2017 update.

Authors:  Francesca Marini; Luisella Cianferotti; Francesca Giusti; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2017-05-30

3.  Mortality factors in recurrent parathyroid cancer: a pooled analysis.

Authors:  Wen-Hsuan Tsai; Yi-Hong Zeng; Chun-Chuan Lee; Ming-Chieh Tsai
Journal:  J Bone Miner Metab       Date:  2022-02-20       Impact factor: 2.626

4.  Association of Famine Exposure on the Changing Clinical Phenotypes of Primary Hyperparathyroidism in 20 years.

Authors:  Tian-Jiao Yuan; Yu-Ying Yang; Min-Ting Zhu; Yang He; Lin Zhao; Wen-Zhong Zhou; Ting-Wei Su; Hong-Yan Zhao; Li-Hao Sun; Bei Tao; Jian-Min Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

5.  Genomic profiling reveals mutational landscape in parathyroid carcinomas.

Authors:  Chetanya Pandya; Andrew V Uzilov; Justin Bellizzi; Chun Yee Lau; Aye S Moe; Maya Strahl; Wissam Hamou; Leah C Newman; Marc Y Fink; Yevgeniy Antipin; Willie Yu; Mark Stevenson; Branca M Cavaco; Bin T Teh; Rajesh V Thakker; Hans Morreau; Eric E Schadt; Robert Sebra; Shuyu D Li; Andrew Arnold; Rong Chen
Journal:  JCI Insight       Date:  2017-03-23

6.  Synchronous intrathyroidal parathyroid carcinoma and thyroid carcinoma: case report and review of the literature.

Authors:  Nadia De Falco; Giuseppe Santangelo; Fabrizio Chirico; Angelo Cangiano; Maria Giulia Sommella; Angelo Cosenza; Andrea Ronchi; Marina Accardo; Gianluca Pellino; Domenico Parmeggiani; Silvestro Canonico; Massimo De Falco
Journal:  BMC Endocr Disord       Date:  2021-04-07       Impact factor: 2.763

7.  Analyzing Genetic Differences Between Sporadic Primary and Secondary/Tertiary Hyperparathyroidism by Targeted Next-Generation Panel Sequencing.

Authors:  Yu Ah Hong; Ki Cheol Park; Bong Kyun Kim; Jina Lee; Woo Young Sun; Hae Joung Sul; Kyung-Ah Hwang; Won Jung Choi; Yoon-Kyung Chang; Suk Young Kim; Soyoung Shin; Joonhong Park
Journal:  Endocr Pathol       Date:  2021-07-03       Impact factor: 3.943

Review 8.  Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.

Authors:  Luís Cardoso; Mark Stevenson; Rajesh V Thakker
Journal:  Hum Mutat       Date:  2017-09-25       Impact factor: 4.878

9.  PIK3CA Mutational Analysis of Parathyroid Adenomas.

Authors:  Aaliyah Riccardi; Carolina Lemos; Ryan Ramos; Justin Bellizzi; Kourosh Parham; Taylor C Brown; Reju Korah; Tobias Carling; Jessica Costa-Guda; Andrew Arnold
Journal:  JBMR Plus       Date:  2020-04-13

10.  Molecular analysis of cyclin D1 modulators PRKN and FBX4 as candidate tumor suppressors in sporadic parathyroid adenomas.

Authors:  Kelly Brewer; Isabel Nip; Justin Bellizzi; Jessica Costa-Guda; Andrew Arnold
Journal:  Endocr Connect       Date:  2021-03       Impact factor: 3.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.